Article

Scale-Up And BLA Planning For Microbial Biomanufacturing: When Should You Talk To A CDMO?

By Lonza Biologics

iStock-1212392770-lab-pipette-analysis

Over the last decade, emerging biopharma has been a driving force in innovation and development across the life sciences sector, transforming the industry’s R&D model and reshaping the competitive landscape. However, effectively developing and commercializing biotherapeutics often requires smaller companies and startups to leverage knowledgeable partners that have successfully brought other products to market.

In addition, an increased focus on smaller next-generation biologics, such as antibody mimetics and plasmid DNA, is shifting interest back toward microbial biomanufacture as an effective manufacturing platform.

Ensuring early planning of scale-up and biological license application (BLA) activities for your microbial-based product can maximize your chances of success by allowing sufficient time to develop options for launch, ultimately preventing costly delays and setbacks.

Read the complete article to understand how to make a detailed plan at the beginning with the end in mind.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: